logo
Plus   Neg
Share
Email

Roche Reports FDA Approval Of Rozlytrek - Quick Facts

Roche (RHHBY) announced the US FDA approval of Rozlytrek for the treatment of adults with ROS1-positive, metastatic non-small cell lung cancer. Also, the FDA has granted accelerated approval to Rozlytrek for the treatment of adult and paediatric patients 12 years of age and older with solid tumours that have a neurotrophic tyrosine receptor kinase gene fusion without a known acquired resistance mutation.

Sandra Horning, Roche's Head of Global Product Development, said: "Rozlytrek is the first FDA-approved treatment that selectively targets both ROS1 and NTRK fusions, and, importantly, has also shown responses in these rare cancer types that have spread to the brain."

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Facebook has launched its new payment platform called 'Facebook Pay' in the U.S., joining other tech giants like Google and Apple that have their own payment platforms. The new service will be available across Facebook and its associated apps - Messenger, Instagram and WhatsApp, the social media giant said in a blog post. The payment service supports most major credit and debit cards. Amneal Pharmaceuticals, LLC recalled certain lots of heartburn medication Ranitidine in the form of tablets and syrup for the potential presence of nitrosamine impurity, N-Nitrosodimethylamine, above levels established by the U.S. Food and Drug Administration or FDA. The generic and specialty pharma company is recalling 94 lots of Ranitidine tablets and Syrup. The U.S. Department of Justice said it settled with a Florida-based IT recruiting and staffing company for immigration-related discrimination against non-U.S. citizens, including asylees. Perspective Talent LLC, a Pembroke Pines company, was found by the DOJ to have posted discriminatory job advertisements that unlawfully excluded individuals who are authorized to work in the U.S.
Follow RTT
>